Alios BioPharma and Johnson & Johnson (NYSE: JNJ) have entered into a definitive agreement in which J&J will acquire Alios for $1.75 billion in cash. The deal, expected to close in 4Q, will be one of the largest acquisitions of a VC-backed biopharma on record. Alios develops novel therapies for the treatment of viral diseases. At the time of the agreement, it had raised over $76.5 million in VC funding from firms including Roche Venture Fund, Novartis Venture Funds, Novo and SR One. The company's lead compound, AL-8176, is an oral treatment for viral infections including respiratory syncytial virus, influenza, rhinovirus and coronavirus; it will complement J&J's existing portfolio for RSV, which is the leading cause of respiratory infection in children. Goldman Sachs served as exclusive financial advisor to Alios; Latham Watkins was its legal advisor.